Suzanne G. M. A. Pasmans

Suzanne G. M. A. Pasmans

Auto-generated profile, based on publicly available information

Suzanne G. M. A. Pasmans

Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2014 in Journal of Medical Internet Research
Verified
Journal Article
Open access
NENiels J Elbert
Niels J Elbert
HOHarmieke van Os-Medendorp
Harmieke van Os-Medendorp
WRWilco van Renselaar
Wilco van Renselaar
AEAnne G Ekeland
Anne G Ekeland
LRLeona Hakkaart-Van Roijen
Leona Hakkaart-Van Roijen
SPSuzanne Gma Pasmans
Suzanne Gma Pasmans
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

22 May 2017 in Case Reports in Dermatology
Verified
Journal Article
Open access
PDF file
JTJoan E.E. Totté
Joan E.E. Totté
MDMartijn B. van Doorn
Martijn B. van Doorn
SPSuzanne G.M.A. Pasmans
Suzanne G.M.A. Pasmans
Staphylococcus aureus plays an important role in skin and soft tissue infections and contributes to the pathophysiology of complex skin disorders such as atopic dermatitis. Bacterial resistance against commonly used antibiotics has increased considerably in the last decades demanding alternative treatment approaches. We present 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100. Staphefekt SA.100 is a recombinant phage endolysin for topical skin application that specifically targets both methicillin-sensitive and methicillin-resistant S. aureus. As a consequence of its specific mechanism of action, bacterial resistance is unlikely to develop. In our 3 cases, resistance induction was not observed. Our results indicate that targeted treatment with Staphefekt might be an attractive alternative for (long-term) classical antibiotic therapy, and confirmatory randomized controlled trials are warranted to evaluate its clinical efficacy and safety.

25 January 2018 in International Archives of Allergy and Immunology
Verified
Journal Article
Open access
PDF file
KFKarin B. Fieten
Karin B. Fieten
JTJoan E.E. Totté
Joan E.E. Totté
ELEvgeni Levin
Evgeni Levin
MRMarta Reyman
Marta Reyman
YMYolanda Meijer
Yolanda Meijer
SPSuzanne G.M.A. Pasmans
Suzanne G.M.A. Pasmans
Background: Exposure to microbes may be important in the development of atopic disease. Atopic diseases have been associated with specific characteristics of the intestinal microbiome. The link between intestinal microbiota and food allergy has rarely been studied, and the gold standard for diagnosing food allergy (double-blind placebo-controlled food challenge [DBPCFC]) has seldom been used. We aimed to distinguish fecal microbial signatures for food allergy in children with atopic dermatitis (AD). Methods: Pediatric patients with AD, with and without food allergy, were included in this cross-sectional observational pilot study. AD was diagnosed according to the UK Working Party criteria. Food allergy was defined as a positive DBPCFC or a convincing clinical history, in combination with sensitization to the relevant food allergen. Fecal samples were analyzed using 16S rRNA microbial analysis. Microbial signature species, discriminating between the presence and absence food allergy, were selected by elastic net regression. Results: Eighty-two children with AD (39 girls) with a median age of 2.5 years, and 20 of whom were diagnosed with food allergy, provided fecal samples. Food allergy to peanut and cow's milk was the most common. Six bacterial species from the fecal microbiome were identified, that, when combined, distinguished between children with and without food allergy: Bifidobacterium breve, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Escherichia coli, Faecalibacterium prausnitzii, and Akkermansia muciniphila (AUC 0.83, sensitivity 0.77, specificity 0.80). Conclusions: In this pilot study, we identified a microbial signature in children with AD that discriminates between the absence and presence of food allergy. Future studies are needed to confirm our findings.

31 August 2017 in Trials
Verified
Journal Article
Open access
PDF file
JTJoan Totté
Joan Totté
JWJill de Wit
Jill de Wit
LPLuba Pardo
Luba Pardo
FSFrank HJ Schuren
Frank HJ Schuren
MDMartijn van Doorn
Martijn van Doorn
SPSuzanne Pasmans
Suzanne Pasmans
Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its effect as long-term anti-staphylococcal treatment in non-infected AD. This is a multi-centre, placebo-controlled, double-blinded and randomized superiority trial with a parallel group design. A total of 100 participants, aged 18 years or older, diagnosed with moderate to severe AD and using a topical corticosteroid in the weeks before enrolment are included in the study. The study is executed in the Erasmus MC University Medical Centre Rotterdam in collaboration with the Havenziekenhuis Rotterdam. After a 2-week run-in period to standardize the corticosteroid use with triamcinolone acetonide 0.1% cream, participants will be randomized to either treatment with Staphefekt in a cetomacrogol-based cream or a placebo for 12 weeks, followed by an 8-week follow-up period. The primary objective is to assess the difference in the need for corticosteroid co-therapy between the Staphefekt and the placebo group, measuring the number of days per week of corticosteroid cream (triamcinolone) use. Secondary outcomes include the difference in use of corticosteroid cream measured in grams, differences in clinical efficacy, quality of life (QoL), microbial composition (includi23ng S. aureus) between the Staphefekt and the placebo group, and the safety and tolerability. The results of this trial will provide data about the effect of long-term anti-staphylococcal therapy with Staphefekt on corticosteroid use, clinical symptoms and QoL in patients with moderate to severe AD. Additional data about growth characteristics of the skin microbiome, including S. aureus, will give insight into the role of the microbiome as a factor in the pathophysiology of AD. ClinicalTrials.gov, NCT02840955 . Registered on 11 July 2016.

1 September 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JWJill de Wit
Jill de Wit
JTJoan E.E. Totté
Joan E.E. Totté
MMMinke M.F. van Mierlo
Minke M.F. van Mierlo
JVJoyce van Veldhuizen
Joyce van Veldhuizen
MDMartijn B.A. van Doorn
Martijn B.A. van Doorn
SPSuzanne G.M.A. Pasmans
Suzanne G.M.A. Pasmans

15 February 2022 in Allergy
Verified
Journal Article
Open access
PDF file
KFKarin B. Fieten
Karin B. Fieten
MDMarieke T. Drijver‐Messelink
Marieke T. Drijver‐Messelink
ACAnnalisa Cogo
Annalisa Cogo
DCDenis Charpin
Denis Charpin
MSMilena Sokolowska
Milena Sokolowska
CACezmi A. Akdis
Cezmi A. Akdis
Currently available European Alpine Altitude Climate Treatment (AACT) programs combine the physical characteristics of altitude with the avoidance of environmental triggers in the alpine climate and a personalized multidisciplinary pulmonary rehabilitation approach. The reduced barometric pressure, oxygen pressure, and air density, the relatively low temperature and humidity, and the increased UV radiation at moderate altitude induce several physiological and immunological adaptation responses. The environmental characteristics of the alpine climate include reduced aeroallergens such as house dust mites (HDM), pollen, fungi, and less air pollution. These combined factors seem to have immunomodulatory effects controlling pathogenic inflammatory responses and favoring less neuro‐immune stress in patients with different asthma phenotypes. The extensive multidisciplinary treatment program may further contribute to the observed clinical improvement by AACT in asthma control and quality of life, fewer exacerbations and hospitalizations, reduced need for oral corticosteroids (OCS), improved lung function, decreased airway hyperresponsiveness (AHR), improved exercise tolerance, and improved sinonasal outcomes. Based on observational studies and expert opinion, AACT represents a valuable therapy for those patients irrespective of their asthma phenotype, who cannot achieve optimal control of their complex condition despite all the advances in medical science and treatment according to guidelines, and therefore run the risk of falling into a downward spiral of loss of physical and mental health. In the light of the observed rapid decrease in inflammation and immunomodulatory effects, AACT can be considered as a natural treatment that targets biological pathways.